CO2019002607A2 - Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto - Google Patents
Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contactoInfo
- Publication number
- CO2019002607A2 CO2019002607A2 CONC2019/0002607A CO2019002607A CO2019002607A2 CO 2019002607 A2 CO2019002607 A2 CO 2019002607A2 CO 2019002607 A CO2019002607 A CO 2019002607A CO 2019002607 A2 CO2019002607 A2 CO 2019002607A2
- Authority
- CO
- Colombia
- Prior art keywords
- activation system
- biomarkers
- metabolites
- contact activation
- diseases associated
- Prior art date
Links
- 230000004913 activation Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 239000002207 metabolite Substances 0.000 title 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395770P | 2016-09-16 | 2016-09-16 | |
| US201762518367P | 2017-06-12 | 2017-06-12 | |
| PCT/US2017/051755 WO2018053247A1 (en) | 2016-09-16 | 2017-09-15 | Metabolite biomarkers for diseases associated with the contact activation system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019002607A2 true CO2019002607A2 (es) | 2019-03-29 |
Family
ID=59974882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0002607A CO2019002607A2 (es) | 2016-09-16 | 2019-03-21 | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11340237B2 (enExample) |
| EP (1) | EP3513197A1 (enExample) |
| JP (4) | JP7225090B2 (enExample) |
| KR (3) | KR20250030022A (enExample) |
| CN (2) | CN117169508A (enExample) |
| AU (2) | AU2017325986B2 (enExample) |
| CA (1) | CA3037157A1 (enExample) |
| CO (1) | CO2019002607A2 (enExample) |
| IL (2) | IL314752A (enExample) |
| MX (2) | MX2019002918A (enExample) |
| NZ (1) | NZ792393A (enExample) |
| WO (1) | WO2018053247A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| IL314752A (en) | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
| KR20250073510A (ko) | 2016-09-16 | 2025-05-27 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| US12181462B2 (en) | 2019-07-25 | 2024-12-31 | Overture Life, Inc. | Identification of viable human embryos |
| CN110514772A (zh) * | 2019-08-09 | 2019-11-29 | 中国医学科学院基础医学研究所 | 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用 |
| MX2022008649A (es) | 2020-01-13 | 2022-09-23 | Takeda Pharmaceuticals Co | Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico. |
| EP4126219A2 (en) * | 2020-04-04 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113495137A (zh) * | 2021-06-29 | 2021-10-12 | 江苏省中医院 | 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用 |
| CN117310059B (zh) * | 2023-11-30 | 2024-02-02 | 中国人民解放军总医院 | 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| EP1711828A2 (en) | 2004-01-28 | 2006-10-18 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2) |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP2177908A3 (en) | 2005-10-11 | 2010-05-19 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| AU2007281220B2 (en) * | 2006-07-31 | 2013-08-15 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| EP2069778A2 (en) | 2006-08-03 | 2009-06-17 | Numira Biosciences, Inc. | Methods and compositions for identifying biomarkers |
| EP2102357B1 (en) | 2006-10-16 | 2013-11-27 | Bayer Intellectual Property GmbH | Ltbp2 as a biomarker, therapeutic and diagnostic target |
| WO2008046528A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Npr3 as a biomarker, therapeutic and diagnostic target |
| ES2383235T3 (es) | 2006-10-16 | 2012-06-19 | Bayer Pharma Aktiengesellschaft | CTGF como biomarcador , diana terapéutica y diagnóstica |
| WO2008046508A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Tgfb2 as a biomarker, therapeutic and diagnostic target |
| US20100081136A1 (en) | 2006-10-16 | 2010-04-01 | Stefan Golz | Crtac as a biomarker, therapeutic and diagnostic target |
| WO2008046510A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Fn1 as a biomarker, therapeutic and diagnostic target |
| WO2008046512A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Prss23 as a biomarker, therapeutic and diagnostic target |
| FR2914066B1 (fr) * | 2007-03-20 | 2009-05-22 | Polyintell Sarl | Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant |
| PL2281204T3 (pl) | 2008-04-29 | 2014-06-30 | Psychemedics Corp | Wieloanalitowa analiza w fazie stałej dla nadużywanych narkotyków i ich metabolitów |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
| CN102667485B (zh) | 2009-08-12 | 2015-04-22 | 福满代谢组技术有限公司 | 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质 |
| US20110098993A1 (en) | 2009-10-27 | 2011-04-28 | Anaxomics Biotech Sl. | Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data |
| WO2011053831A1 (en) * | 2009-10-30 | 2011-05-05 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2502079B1 (en) | 2009-11-20 | 2015-01-28 | Pharnext | New diagnostic tools for charcot-marie-tooth disease |
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| WO2011119772A1 (en) | 2010-03-23 | 2011-09-29 | Purdue Research Foundation | Early detection of recurrent breast cancer using metabolite profiling |
| US20120040383A1 (en) | 2010-08-12 | 2012-02-16 | Wei Jia | Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| JP5986440B2 (ja) | 2012-07-05 | 2016-09-06 | 国立医薬品食品衛生研究所長 | アルツハイマー病の発症を予測する方法 |
| CN114949001A (zh) | 2012-08-29 | 2022-08-30 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| US20140086825A1 (en) | 2012-09-24 | 2014-03-27 | William J. McFaul | Methods and kits for assessing, modulating and treating substances affecting bodily processes |
| HRP20190528T1 (hr) | 2013-01-20 | 2019-05-17 | Dyax Corp. | PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL |
| IL273688B2 (en) | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016514141A (ja) | 2013-03-14 | 2016-05-19 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法 |
| RU2637946C2 (ru) * | 2013-03-15 | 2017-12-08 | Интрексон Корпорейшн | Борсодержащие диацилгидразины |
| EP3060582B1 (en) | 2013-10-21 | 2020-09-23 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| EP2884282A1 (en) * | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| ES2825105T3 (es) | 2014-04-08 | 2021-05-14 | Metabolon Inc | Obtención del perfil bioquímico de moléculas pequeñas de sujetos individuales para el diagnóstico de enfermedad y evaluación de la salud |
| AU2015321470B2 (en) | 2014-09-22 | 2018-11-15 | National Health Research Institutes | Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases |
| IL305207A (en) * | 2015-03-30 | 2023-10-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema |
| IL311909B1 (en) | 2015-08-13 | 2025-11-01 | Takeda Pharmaceuticals Co | Method for assesing the level of drug targeting the contact system in a subject |
| JP6570472B2 (ja) | 2016-03-30 | 2019-09-04 | 株式会社マンダム | 毛髪の損傷の評価方法 |
| KR20250073510A (ko) | 2016-09-16 | 2025-05-27 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| JP7319916B2 (ja) | 2016-09-16 | 2023-08-02 | 武田薬品工業株式会社 | 遺伝性血管性浮腫のｒｎａバイオマーカー |
| IL314752A (en) | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
-
2017
- 2017-09-15 IL IL314752A patent/IL314752A/en unknown
- 2017-09-15 KR KR1020257006143A patent/KR20250030022A/ko active Pending
- 2017-09-15 CN CN202310782203.XA patent/CN117169508A/zh active Pending
- 2017-09-15 EP EP17777137.5A patent/EP3513197A1/en active Pending
- 2017-09-15 KR KR1020197010802A patent/KR102464380B1/ko active Active
- 2017-09-15 AU AU2017325986A patent/AU2017325986B2/en active Active
- 2017-09-15 IL IL265199A patent/IL265199B2/en unknown
- 2017-09-15 NZ NZ792393A patent/NZ792393A/en unknown
- 2017-09-15 CN CN201780057052.4A patent/CN109716137B/zh active Active
- 2017-09-15 MX MX2019002918A patent/MX2019002918A/es unknown
- 2017-09-15 US US16/333,101 patent/US11340237B2/en active Active
- 2017-09-15 KR KR1020227038426A patent/KR102775437B1/ko active Active
- 2017-09-15 JP JP2019514825A patent/JP7225090B2/ja active Active
- 2017-09-15 CA CA3037157A patent/CA3037157A1/en active Pending
- 2017-09-15 WO PCT/US2017/051755 patent/WO2018053247A1/en not_active Ceased
-
2019
- 2019-03-13 MX MX2024004195A patent/MX2024004195A/es unknown
- 2019-03-21 CO CONC2019/0002607A patent/CO2019002607A2/es unknown
-
2022
- 2022-04-25 US US17/728,285 patent/US12188948B2/en active Active
-
2023
- 2023-02-08 JP JP2023017898A patent/JP7451791B2/ja active Active
-
2024
- 2024-01-30 AU AU2024200561A patent/AU2024200561B2/en active Active
- 2024-03-06 JP JP2024034012A patent/JP7692508B2/ja active Active
- 2024-11-26 US US18/960,119 patent/US20250199014A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092519A patent/JP2025124816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019002607A2 (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto | |
| CO2019002608A2 (es) | Biomarcadores de arn para angioedema hereditario | |
| GB2556004A (en) | Markers of stroke and stroke severity | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| MX2021001659A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| MX2017005888A (es) | Dispositivos, sistemas y metodos para la deteccion de analitos. | |
| CO2019012771A2 (es) | Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos | |
| MX387936B (es) | Metodo para la cuantificacion de huevos de parasitos en las heces. | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| BR112016025627A2 (pt) | biomarcadores e combinações dos mesmos para diagnóstico de tuberculose | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| MX2015006538A (es) | Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa. | |
| BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
| MX2019003569A (es) | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. | |
| CO2019006234A2 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal | |
| CO2019002751A2 (es) | Composiciones marcadoras, y metodos para fabricar y usar las mismas | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| MX2018002354A (es) | Métodos para el tratamiento de una enfermedad poliquística renal. | |
| MX2017001134A (es) | Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana. | |
| MX2020005319A (es) | Ensayo mediado por acido para analizar conjugados de ligando-farmaco. | |
| CL2019002163A1 (es) | Cebadores y métodos de detección de virus de peces. (divisional solicitud 201803875). | |
| CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto |